DA 3201

Drug Profile

DA 3201

Alternative Names: DA-3201; Recombinant basic fibroblast growth factor (DA-3201)

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Antivirals; Fibroblast growth factors; Growth factors; Interferons
  • Mechanism of Action Fibroblast growth factor receptor modulators; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma; Chronic obstructive pulmonary disease; Hepatitis C

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease; Hepatitis C

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in South Korea
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in South Korea
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top